• Acute coronary syndrome (ACS) with atrial fibrillation (AF) is a therapeutic challenge.
Summary. Background: Dual antithrombotic therapy comprising a vitamin K antagonist (VKA) plus clopidogrel reduces the incidence of major bleeding compared with triple therapy (VKA + clopidogrel + aspirin) in acute coronary syndrome (ACS) patients with atrial fibrillation (AF), with a similar thrombotic risk. The oral thrombin inhibitor dabigatran (150 mg twice a day) showed superiority over VKA in non-valvular AF, but data supporting its use in AF patients presenting with ACS are limited. Objective: We sought to evaluate the efficacy of dabigatran vs. VKA in the management of AF patients undergoing percutaneous coronary intervention for an ACS. Methods: In this open-label study, 133 consecutive patients received dabigatran plus clopidogrel. Another cohort of 133 patients treated with VKA plus clopidogrel was used as the control group. Results: After propensity score adjustment, the cumulative incidence of major adverse cardiovascular events over 24 months was higher
Introduction
Presentation with coronary artery disease and atrial fibrillation (AF) is a common clinical scenario [1, 2] and is associated with higher mortality rates compared with either condition alone [2] . The antithrombotic management of such patients presents a therapeutic challenge, particularly in the event of an acute coronary syndrome (ACS), taking into account prevention of stroke using oral anticoagulants and prevention of recurrent coronary events using antiplatelet therapy [3] .
With respect to long-term antithrombotic treatment after percutaneous coronary intervention (PCI), extended exposure to triple therapy, typically comprising aspirin, clopidogrel and a vitamin K antagonist (VKA), is associated with an increased risk of bleeding compared with dual antiplatelet therapy [4] . In addition, occurrence of major bleeding is associated with an up to 5-fold increased risk of death following an ACS [4] [5] [6] [7] . The WOEST trial [8] showed a significant reduction in the rate of bleeding with dual (VKA plus clopidogrel) vs. triple therapy; although the trial was not powered to detect difference in thrombotic events, no increase in ischemic events was observed. Other registries have since confirmed the role of VKA plus clopidogrel in AF patients who undergo PCI [9] [10] [11] . Whereas large trials that assess ischemic outcomes and potential differences in rates of major bleeding are lacking, guidelines consider it reasonable to use dual therapy with an oral anticoagulant and clopidogrel without aspirin in this setting [12, 13] .
Over the past decade, the direct oral thrombin inhibitor dabigatran and the factor (F) Xa inhibitors rivaroxaban and apixaban have demonstrated their benefit over VKA for stroke prevention in non-valvular AF (NVAF) in terms of reducing bleeding rates and removing the need for laboratory monitoring [14] . Consequently, their potential as antithrombotic therapy after an ACS has been investigated. Recently, the safety and efficacy of low-dose rivaroxaban in association with a P2Y 12 inhibitor for 12 months was associated with a lower rate of clinically significant bleeding vs. standard therapy with a VKA and dual antiplatelet therapy [15] . In the RE-LY trial [16] , dabigatran 110 mg twice a day resulted in a lower rate of major bleeding events and similar rates of stroke or systemic embolism vs. warfarin. These benefits were observed irrespective of concomitant treatment with single or dual antiplatelet therapy [17] . However, a trend towards a higher incidence of myocardial infarction was observed in dabigatran-treated patients [18] . Prospective data on dabigatran in this population undergoing PCI are still needed. We therefore sought to evaluate the outcomes associated with dual therapy with dabigatran plus clopidogrel vs. VKA dual therapy (fluindione plus clopidogrel) in ACS patients with NVAF.
Methods

Study design and eligibility criteria
This open-label, single-center study was conducted in the Cardiology Department of the University Hospital Nord of Marseille. One hundred and thirty-three consecutive patients presenting with NVAF and admitted to our institution for emergency PCI between November 2012 and November 2014 were eligible. The inclusion criterion was PCI with stent implantation for persistent ST-elevation or non-ST-elevation ACS, as defined in the European Society of Cardiology guidelines [13] . All 133 patients received treatment with dabigatran 110 mg twice a day, in combination with clopidogrel 75 mg day
À1
. Another cohort including 356 patients with NVAF presenting with ACS and treated with fluindione plus clopidogrel from 2008 to 2012 served as a control group [19] . To avoid a 'period effect', the 133 most recently enrolled patients in this secondary cohort were considered for the present study (Fig. 1) . All of the patients were on dual therapy (oral anticoagulant and clopidogrel, omitting oral aspirin just after completing PCI). This dual therapy was continued for at least 1 year. Exclusion criteria were severe chronic kidney disease, history of intracranial bleeding, cardiogenic shock, contraindication for aspirin or clopidogrel, peptic ulcer in the previous 6 months, thrombocytopenia, major bleeding (Thrombolysis In Myocardial Infarction [TIMI] criteria) in the past 12 months, and pregnancy. The study was conducted in accordance with the principles laid out in the Declaration of Helsinki. The protocol was approved by the local ethics committee. All participants provided informed written consent.
Periprocedural antithrombotic management
During PCI, additional low-dose parenteral anticoagulation (heparin bolus, 100 IU kg
À1
) was administered in all dabigatran-treated patients, as suggested by Vranckx et al. [20] . In VKA-treated patients, PCI was performed without interruption of VKA and without additional anticoagulation, per the guidelines [21] .
In both groups, all patients received a bolus of 250 mg aspirin intravenously and a loading dose of 600 mg clopidogrel followed by 75 mg daily. In both groups, aspirin was discontinued the day after PCI, according to the guidelines (grade IIb recommendation) [3] . Proton pump inhibitors were administered to prevent gastrointestinal bleeding.
High on-treatment platelet reactivity
Because poor responsiveness to clopidogrel is common, P2Y 12 -adenosine diphosphate receptor blockade was assessed using the vasodilator stimulated phosphoprotein (VASP) index [22] . Patients with a VASP index > 50% were considered to have high on-treatment platelet reactivity. Because VKA or dabigatran may modify responsiveness to clopidogrel, antiplatelet therapy was tailored according to the presence of high on-treatment platelet reactivity, with a supplementary loading dose of clopidogrel given to obtain a VASP index < 50% [23] .
Coronary angiography
Whenever possible, PCI was performed via the radial route to reduce the risk of access site bleeding, and drugeluting stents (DES) were preferred over bare-metal stents in all patients.
International normalized ratio and time in therapeutic range
International normalized ratio measures were acquired conventionally, at the discretion of the practitioner at the local laboratory (at least once a month), and dose adjustments were made accordingly.
Outcomes
The primary efficacy outcome was a composite of major adverse cardiovascular events (MACE), defined as all-cause death (including vascular death), myocardial infarction, stent thrombosis, ischemia-driven revascularization, or stroke (ischemic or hemorrhagic), over 24 months. Deaths from vascular causes were defined as death from cardiovascular or cerebrovascular causes and any death without another known cause. New Q-wave myocardial infarction was defined per the universal definition [24] . Periprocedural myocardial infarctions were excluded. Each one of the various events included in the composite efficacy outcome was considered independently as a secondary efficacy outcome. The safety outcome was defined as severe bleeding, according to the Bleeding Academic Research Consortium (BARC) criteria for major (BARC 2, 3a, 3b, 3c and 5) bleeding events [25] . An independent central committee adjudicated all suspected efficacy and safety events.
Data collection
Follow-up data after discharge were obtained during routine scheduled outpatient visits at 1 month and during telephone calls to patients every 3 months according to the clinical evolution of each patient. Standardized questions were used to assess bleeding episodes, thrombotic events and use of medications. All thrombotic and bleeding events requiring medical attention were verified by an events committee that was unaware of the patient's study group, by use of medical records obtained from referring family doctors and hospitals. All patients completed the follow-up period.
Statistical analyses
Continuous data are expressed as mean (range or standard deviation) and categorical data as absolute value and percentage. Statistical analyses were performed on an intention-to-treat principle. Clinical and angiographic characteristics of the patients were described for the two groups of treatment and compared. For quantitative variables, Student's t-tests were performed when valid; Mann-Whitney tests were performed otherwise. For qualitative variables, chi-squared tests were performed when valid; Fisher's exact tests were performed otherwise.
Outcomes were compared between the two treatment groups using a time-to-event approach. For MACE and for death outcomes, Kaplan-Meier curves were plotted and the Cox regression model was used, which allowed the estimation of hazard ratios with their 95% confidence intervals. For all other outcomes, their occurrence may be precluded by death, creating a context of competing risks [26] ; therefore, the analysis accounted for this potential bias [27] . The analysis was limited to the first occurring event in the competing risks framework using the following quantities commonly used to summarize outcomes by event type: (i) the cause-specific hazard function, which for each event can heuristically be thought of as the probability of event in a small interval of time, given that no death occurred before; and (ii) the cumulative incidence function, which for each event corresponds to the probability of event in the presence of competing death events. Cumulative incidence curves were plotted and the Fine and Gray model was used, which allowed the estimation of sub-distribution hazard ratios with their 95% confidence intervals [28, 29] . The proportional hazards assumption was assessed by testing covariate interactions with quadratic function of time and was checked graphically using Schoenfeld-type residuals.
To reduce confounding by indication, adjustment was performed for factors favoring selection of dabigatran plus clopidogrel therapy using a propensity score, with baseline clinical variables at the time of PCI (age, sex, HAS-BLED, CRUSADE, CHA 2 DS 2 -VASc and GRACE scores). The C-statistic value for the propensity model was 0.703. Cox and Fine and Gray analyses were carried out using treatment group and propensity score as covariates. Characteristics potentially associated with the confounding by indication or the risk of event were included in the propensity score but were not proposed as covariates.
All statistics were calculated using R software. The R package cmprsk was used for competing risk analyses. All tests were two-sided. P values < 0.05 were considered significant.
Results
From November 2012 to November 2014, 189 consecutive AF patients admitted for emergency PCI were assessed for eligibility. Dabigatran was not indicated in 56 patients. The remaining 133 patients were assigned to the dabigatran plus clopidogrel group (Fig. 1) . Since 2008, we have set up a cohort including AF patients presenting with ACS on VKA plus clopidogrel treatment, according to the guidelines (grade IIb) [3] . Among the 356 patients on VKA plus clopidogrel included in this cohort, the 133 most recently enrolled ones were considered for the present study (Fig. 1) .
Patient baseline characteristics are detailed in Table 1 . Mean thrombotic scores (CHA 2 DS 2 -VASc and GRACE) at admission and VASP index at discharge were similar in the two groups. The angiographic characteristics were similar between groups, with the exception of a smaller mean stent diameter and longer total stent length in the VKA group (Table 2) .
Outcomes
Cumulative incidence of MACE was higher in the dabigatran group (adjusted hazard ratio, 2.28; 95% confidence interval, 1.46-3.56; P < 0.001) ( Table 3 ). Despite omitting aspirin at the acute phase, most of the MACE occurred at 6 months (Fig. 2) . In particular, all the MACE referring to ischemic events (stent thrombosis, myocardial infarction and ischemia-driven revascularization) occurred at the late phase (from 30 days to 1 year) and at the very late period (after 1 year) (Fig. 3) . The cumulative incidence of spontaneous major bleeding was similar in the two groups (Table 3 ). In the dabigatran group, one patient died from an intracranial hemorrhage (BARC 5), three experienced a BARC 3 event and four experienced a BARC 2 event. In the VKA group, one patient died from an intracranial hemorrhage, three experienced a BARC 3 event and five a BARC 2 event.
Discussion
This is the first across-cohort comparison that evaluated long-term outcomes with dual therapy comprising dabigatran plus clopidogrel vs. VKA plus clopidogrel in AF patients who underwent PCI for an ACS. Our work suggests that thrombotic risk was significantly increased in the dabigatran group. This increased cardiovascular morbidity was apparent despite the VKA group showing high-risk characteristics (higher incidence of dyslipidemia, limited anticoagulation control, higher risk of bleeding and more complex PCI procedure). The rate of major bleeding was, however, similar in the two groups. Interestingly, omitting aspirin during the first month did not increase the rate of ischemic events, such as stent thrombosis, ischemia-driven revascularization or myocardial infarction in the early phase.
Choice of fluindione and dabigatran as oral anticoagulant
In France, fluindione is the VKA of choice, accounting for 78% of prescriptions [26] . The median time in therapeutic range in our cohort was 48%, similar to that reported in French anticoagulation clinics [26] but lower than that in the RE-LY study (64%) [27] or the PIO-NEER AF-PCI study (65%) [15] . Despite poor-quality anticoagulation control in our study, we did not observe an increased risk of ischemic stroke in the VKA group. As direct comparative data are lacking, there is no strong argument for choosing one non-VKA oral anticoagulant over another in this setting. We chose dabigatran, as the most specific data available in 2012, albeit post hoc and non-randomized, were from the RE-LY trial [16, 18] . Where a non-vitamin K antagonist oral anticoagulant (NOAC) is used in combination with clopidogrel, the lower tested dose for stroke prevention in AF (i.e. dabigatran 110 mg twice a day) is recommended [3] .
Antithrombotic strategy
The European Society of Cardiology guidelines propose at least 1 month of triple therapy in AF patients with non-ST-elevation ACS, but these recommendations are relatively weak [3] . In our study, all patients were treated by dual therapy, per IIb-level recommendations [3, 8, 30] . Interestingly the omission of aspirin during the first month while maintaining clopidogrel did not increase the ischemic event rate [8, 31, 32] . All cases of stent thrombosis, myocardial infarction and ischemia-driven revascularization occurred late (> 30 days) or very late (> 1 year).
In the WOEST trial [8] , 1-year all-cause mortality was lower in the dual-therapy group (oral anticoagulant plus clopidogrel) vs. the triple-therapy group (oral anticoagulant plus clopidogrel plus aspirin) (2.5% vs. 6.4%; P = 0.027), whereas the rates of myocardial infarction, stroke, revascularization and stent thrombosis did not differ. In this trial, one-third of patients presented with non-ST-elevation ACS, and PCI was performed via a femoral access site in 74%. The Danish registry [11] , which involved more than 12 000 patients with AF who had a myocardial infarction or underwent PCI, seems to provide sufficient power to infer that dual therapy with VKA and clopidogrel is safe in terms of thrombotic and thromboembolic complications such as myocardial infarction and ischemic stroke. The main objective of the large RE-DUAL PCI trial was to evaluate dual antithrombotic therapy with dabigatran etexilate and a P2Y 12 inhibitor compared with triple antithrombotic therapy in non-valvular AF patients who have undergone PCI with stenting. Unfortunately, in this trial, dabigatran plus clopidogrel was compared with triple antithrombotic therapy, but was not assessed in a head-to-head comparison with another dual therapy such as VKA plus clopidogrel. Moreover, our modest-size study is the first study to tailor antiplatelet therapy based on the presence of high on-treatment platelet reactivity to avoid poor responsiveness to clopidogrel and confirm that omitting aspirin is not a taboo. Furthermore, despite more favorable patient features (stent thrombosis criteria, HAS-BLED, CRUSADE, CHA 2 DS 2 -VASc and GRACE scores) we noticed an increase in the rate of MACE in the dabigatran group, with and without adjustment on the propensity score.
Outcomes
The cumulative incidence of major bleeding in our study (6.0%) was lower than that reported in the PIONEER-AF PCI study [15] . This finding may reflect the fact that we used a single antiplatelet strategy in this highrisk population. In the RE-LY trial, dual antiplatelet therapy increased the bleeding rate by 50-100% regardless of the anticoagulant used [27] . Second, the BARC definition is more influenced by minor bleedings than the TIMI or GUSTO definitions [25] . Third, to reduce bleeding risk, whenever possible we used the radial route and patients were systematically given proton pump inhibitors.
Non-VKA oral anticoagulants
The rates of myocardial infarction reported in individual studies involving non-VKA oral anticoagulants vary [18, 28, 29] . In three recent studies, one of which was a network meta-analysis, the risk of myocardial infarction was greater with dabigatran compared with VKA or other non-VKA oral anticoagulants [30, 33, 34] . However, other studies suggest a group-specific effect for oral thrombin inhibitors, thus an increased rate of acute coronary events was observed with ximelagatran, bivalirudin and AZD083 [35] . Recently, Petzold et al. [36] showed that oral thrombin inhibitor treatment has prothrombotic activity that might contribute to the increase in morbidity observed clinically, and trigger thrombin GPIb signaling platelets. Moreover, dabigatran has recently been shown to increase platelet reactivity by enhancing thrombin receptor density on thrombocytes [37] .
Study limitations
This was a non-randomized, single-center trial. Despite a significant difference in the rates of the primary outcome, a lack of statistical power prevents us from drawing firm conclusions about the individual event rates.
Conclusion
Because of their efficacy and safety profiles, especially with respect to lower rates of intracranial hemorrhage, non-VKA oral anticoagulants may have a role in AF patients experiencing an ACS. However, compared with VKA plus clopidogrel, dabigatran plus clopidogrel increased the risk of MACE without reducing the rate of spontaneous major bleeding in patients with AF who underwent PCI. This study is the first observational across-cohort comparison of these two strategies in the setting of ACS, with a tailored antiplatelet strategy. Our findings suggest that non-VKA oral anticoagulants may increase the risk of ACS through prothrombotic activity. Despite lacking statistical power, these findings provide preliminary evidence that dabigatran should be used with caution in patients at high thrombotic risk. Further studies are necessary to further clarify the risks and benefits of non-VKA oral anticoagulants in coronary artery disease without aspirin medication.
Impact on daily practice
In atrial fibrillation patients undergoing percutaneous intervention for acute coronary syndrome (ACS), replacement of vitamin K antagonists by dabigatran (110 mg twice a day) in association with clopidogrel is associated with an increased thrombotic risk, without a reduction in major bleeding. Use of dabigatran (110 mg twice a day) should be avoided in ACS patients at high thrombotic risk. Randomized trial data are needed to confirm the findings in our study.
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